S-1/A: Applied DNA Sciences Eyes $8.97 Million Boost Through Unit Offering to Advance DNA Production and Testing

Applied DNA Sciences aims to raise approximately $8.97 million through a unit offering to further develop its Therapeutic DNA Production and MDx Testing Services.

Summary

• Applied DNA Sciences is offering 5,319,149 units, each consisting of one share of common stock (or a pre-funded warrant), a Series A warrant, and a Series B warrant, with an assumed offering price of $1.88 per unit.
• The company intends to use the net proceeds of approximately $8.97 million for the further development of its Therapeutic DNA Production and MDx Testing Services, as well as for general corporate purposes.
• The offering includes pre-funded warrants for purchasers who would otherwise exceed beneficial ownership limits of 4.99% or 9.99%.
• The Series A warrants are exercisable at a price of $ per share and expire five years from the closing date, while the Series B warrants are exercisable at $ per share and expire one year from the Warrant Stockholder Approval or the closing date.
• The company is also issuing placement agent warrants to the co-placement agents, Craig-Hallum Capital Group LLC and Laidlaw & Company (UK) Ltd., to purchase shares equal to 5.0% of the units offered.
• The offering is expected to terminate on June 30, 2024, and there is no minimum number of securities or minimum aggregate amount of proceeds required as a condition of the closing.
• The company's strategy focuses on expanding its contract development and manufacturing operation (CDMO) for synthetic DNA and further commercializing its MDx Testing Services through genetic testing.
• The company is developing Linea DNA and Linea IVT platforms for manufacturing synthetic DNA for nucleic acid-based therapeutics.
• The company is planning to offer GMP-grade Linea DNA for starting materials in Q3 of CY2024 and for biologic drug substances in the second half of CY2025, dependent on future financing.
• The company is seeking stockholder approval for certain warrant provisions, including the alternative cashless exercise option in the Series B warrants and the floor price reset mechanism in the Series A warrants.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is pursuing growth opportunities and has innovative technologies, there are significant financial risks and uncertainties, including a history of net losses, doubt about its ability to continue as a going concern, and non-compliance with Nasdaq listing requirements.

Positives

• The offering will provide capital to further develop Therapeutic DNA Production and MDx Testing Services.
• The company is expanding its CDMO for synthetic DNA, tapping into the growing market for nucleic acid-based therapies.
• The company is planning to offer GMP-grade Linea DNA, which could significantly increase revenue potential.
• The company is leveraging its expertise in PCR to develop and commercialize DNA and RNA technologies.
• The company is working to secure commercial-scale supply contracts with clinical and commercial mRNA manufacturers.

Negatives

• The company has a history of net losses and substantial doubt about its ability to continue as a going concern.
• The offering is a best-efforts offering with no guarantee of raising the full amount.
• The company's stock price is volatile, and the reverse stock split may adversely impact the market price.
• The company is not in compliance with the minimum stockholders equity requirement for continued listing on The Nasdaq Capital Market.
• The company needs to obtain stockholder approval for certain warrant provisions, and failure to do so could reduce the value of the warrants.

Risks

• The company's limited revenue makes it difficult to evaluate future prospects.
• The company may require additional financing, which could dilute existing stockholders.
• The company's operating results could be adversely affected by a reduction in business with significant customers.
• The company may encounter difficulties in managing its growth.
• The company's current emphasis on Therapeutic DNA Production Services may reduce its ability to maintain and expand existing MDx Testing Services and DNA Tagging and Security Products and Services businesses.
• The company may be unable to expand its DNA manufacturing capacity.
• Rapidly changing technology and extensive competition in synthetic biology could make the services or products the company is developing obsolete or non-competitive.
• The company may be unable to consistently manufacture or source its products to the necessary specifications or in quantities necessary to meet demand on a timely basis and at acceptable performance and cost levels.
• The markets for drug and biologic candidates and synthetic DNA are very competitive.
• The company's intellectual property rights are valuable, and any inability to protect them could reduce the value of the company's products, services and brand.
• Pharmaceutical and biologic-related revenue is generally dependent on regulatory approval, oversight and compliance.
• If the FDA were to begin to enforce regulation of laboratory-developed tests (LDTs), the company could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements in respect of MDx Testing Services.
• If the company fails to comply with laboratory licensing requirements, the company could lose the ability to offer its MDx Testing Services or experience disruptions to its business.
• If the company fails to comply with healthcare laws, the company could face substantial penalties and the company's business, operations and financial conditions could be adversely affected.
• The company has received a deficiency letter from the Nasdaq Staff notifying the company that it is not in compliance with the minimum stockholders equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market and no assurance can be given that the company will be able to maintain its Nasdaq listing.
• The reverse stock split to regain compliance with Nasdaqs Minimum Bid Price Requirement, which was effected on Thursday, April 25, 2024, may adversely impact the market price of the company's common stock.
• The reverse stock split may decrease the liquidity of the company's common stock and as a result the company's common stock may not satisfy the investing requirements of new investors, including institutional investors.
• The effective increase in the number of shares of the company's common stock available for issuance as a result of the company's reverse stock split could result in further dilution to the company's existing stockholders and have anti-takeover implications.

Future Outlook

The company plans to capitalize on the rapid growth of mRNA therapies and expand its Therapeutic DNA Production Services, aiming to secure commercial-scale supply contracts and develop Linea DNA-based vaccines.

Industry Context

The company is positioning itself to capitalize on the growing markets for mRNA therapies and nucleic acid-based therapeutics, where demand for DNA is increasing. The company is also addressing the need for supply chain security and product authentication, particularly in the cotton industry.

Comparison to Industry Standards

• The document mentions ASGCT Gene, Cell & RNA Therapy Landscape: Q1 2024 Quarterly Report as a source for industry data.
• The document mentions the company's Linea DNA platform as an alternative to plasmid-based DNA manufacturing technologies that have supplied the DNA used in biotherapeutics for the past 40 years.
• The document mentions the company's Linea IVT platform as a way to make better mRNA, faster.
• The document mentions the company's PGx Testing Services as a way to provide PGx testing services to large entities, self-insured employers and healthcare providers.

Stakeholder Impact

• Shareholders face potential dilution from the offering and the exercise of warrants.
• Employees may benefit from the company's growth and expansion plans.
• Customers may benefit from the development of new and improved products and services.
• Suppliers may benefit from increased demand for the company's products and services.
• Creditors face risks associated with the company's financial condition and ability to repay debts.

Next Steps

• The company will seek stockholder approval for certain warrant provisions.
• The company must submit a plan to Nasdaq to regain compliance with the Stockholders Equity Requirement by July 1, 2024.
• The company plans to offer GMP-grade Linea DNA for starting materials in Q3 of CY2024 and for biologic drug substances in the second half of CY2025, dependent on future financing.

Key Dates

Keywords

Applied DNA Sciences, unit offering, Therapeutic DNA Production, MDx Testing Services, Linea DNA, Linea IVT, warrants, common stock, placement agents, biotechnology